A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Public ClinicalTrials.gov record NCT03895203. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Study identification
- NCT ID
- NCT03895203
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 852 participants
Conditions and interventions
Conditions
Interventions
- Adalimumab Drug
- Bimekizumab Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2, 2019
- Primary completion
- Aug 16, 2021
- Completion
- Jul 10, 2022
- Last update posted
- Jan 26, 2026
2019 – 2022
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pa0010 50017 | Phoenix | Arizona | 85037 | — |
| Pa0010 50035 | San Diego | California | 92025 | — |
| Pa0010 50004 | Tustin | California | 92780 | — |
| Pa0010 50033 | Palm Harbor | Florida | 34684 | — |
| Pa0010 50037 | Tampa | Florida | 33613 | — |
| Pa0010 50039 | Atlanta | Georgia | 30342 | — |
| Pa0010 50028 | Lexington | Kentucky | 40504 | — |
| Pa0010 50015 | Hagerstown | Maryland | 21742 | — |
| Pa0010 50016 | St Louis | Missouri | 63141 | — |
| Pa0010 50029 | Albuquerque | New Mexico | 87102 | — |
| Pa0010 50010 | Brooklyn | New York | 11201 | — |
| Pa0010 50125 | Charlotte | North Carolina | 28210 | — |
| Pa0010 50040 | Dayton | Ohio | 45417 | — |
| Pa0010 50020 | Duncansville | Pennsylvania | 16635 | — |
| Pa0010 50006 | Wyomissing | Pennsylvania | 19610 | — |
| Pa0010 50008 | Johnston | Rhode Island | 02919 | — |
| Pa0010 50007 | Orangeburg | South Carolina | 29118 | — |
| Pa0010 50001 | Jackson | Tennessee | 38305 | — |
| Pa0010 50012 | Memphis | Tennessee | 38119 | — |
| Pa0010 50002 | Austin | Texas | 78731 | — |
| Pa0010 50049 | Corpus Christi | Texas | 78404 | — |
| Pa0010 50051 | Houston | Texas | 77034 | — |
| Pa0010 50036 | Mesquite | Texas | 75150 | — |
| Pa0010 50009 | Waco | Texas | 76710 | — |
| Pa0010 50050 | Beckley | West Virginia | 25801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 111 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03895203, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03895203 live on ClinicalTrials.gov.